28 Apr Full year 2021 results and update on growth strategy

Posted at 07:00h in Board, Novacyt Group, Products by

Full year revenue and EBITDA in line with market expectations despite challenging and changing COVID-19 testing market
Leveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years

https://novacyt.com/wp-content/uploads/2022/04/Novacyt-Full-year-2021-results-and-update-on-growth-strategy.pdf